2023 World Conference on Lung Cancer (Posters)-P2.14. Patient-Reported Outcomes from IMfirst: Chemotherapy Plus Atezolizumab in a Real-World Setting of Extensive-Stage SCLC

P2.14. Patient-Reported Outcomes from IMfirst: Chemotherapy Plus Atezolizumab in a Real-World Setting of Extensive-Stage SCLC - PDF(Abstract)

Back to course

Pdf Summary

This document is a summary of a presentation given at the World Conference on Lung Cancer in 2023. The presentation discusses the patient-reported outcomes (PRO) from a trial called IMfirst, which evaluated the use of chemotherapy plus atezolizumab as first-line therapy for small cell lung cancer (SCLC) in a real-world setting. The trial included 155 patients with extensive-stage SCLC in Spain.<br /><br />The study used questionnaires to assess the impact of the treatment on the patients' health-related quality of life (HRQoL), lung cancer-related symptoms, physical functioning, and overall health status. The questionnaires were administered at baseline and at each scheduled study visit during treatment. Clinically meaningful improvements were defined as a 10-point change from baseline.<br /><br />The results showed that there were clinically meaningful changes in treatment-related symptoms, with worsening alopecia and improvement in insomnia and appetite loss. Most lung cancer-related symptoms showed a trend towards improvement, particularly chest pain and cough. The patients' physical functioning and HRQoL also improved throughout the study, with values remaining above baseline at all visits.<br /><br />The authors concluded that the PRO data from the IMfirst trial align with the results observed in a previous trial called IMpower133, suggesting a positive benefit-risk profile of first-line atezolizumab in a broad population of patients with extensive-stage SCLC.<br /><br />In summary, this presentation highlights the positive patient-reported outcomes of a trial evaluating the use of chemotherapy plus atezolizumab as first-line therapy for extensive-stage SCLC. The treatment showed improvements in lung cancer-related symptoms, physical functioning, and HRQoL in a real-world setting.

Asset Subtitle

Manuel Dómine Gómez

Meta Tag

Speaker Manuel Dómine Gómez

Topic SCLC & Neuroendocrine Tumors: First Line Therapy

Keywords

patient-reported outcomes

IMfirst trial

chemotherapy

atezolizumab

SCLC

HRQoL

lung cancer-related symptoms

physical functioning

real-world setting

extensive-stage SCLC